Cytokinetics Under Investigation for Potentially Misleading Investors on Drug Approval Timeline
The law firm Faruqi & Faruqi, LLP has launched an investigation into Cytokinetics, Incorporated (NASDAQ:CYTK) concerning allegations that the company may have misled investors. The probe focuses on the regulatory submission for its drug, aficamten, and its potential impact on the U.S. Food and Drug Administration (FDA) approval timeline.
The investigation centers on the company's New Drug Application (NDA) for aficamten, which was submitted without a Risk Evaluation and Mitigation Strategy (REMS). This information was disclosed during a May 6, 2025, earnings call. The company had previously held several pre-NDA meetings with the FDA but opted for labeling and voluntary education materials instead of a REMS. This decision allegedly led to inflated stock prices, causing significant losses for investors when the details became public. The deadline for lead plaintiff applications for affected investors was November 17, 2025.
In a separate development, a company director, Kaye Edward M. MD, sold 5,175 shares of Cytokinetics stock on November 11, 2025. The shares were sold at an average price of $65.08 each, leaving the director with a holding of 9,977 shares following the transaction.
As of the most recent market data, Cytokinetics' stock was trading at $67.06, a single-day increase of 0.93%, or $0.62. The stock's price fluctuated between $65.33 and $67.98 during the session, with the high marking a new 52-week peak. The stock's lowest price in the past year was $29.31. The company has a market capitalization of approximately $7.98 billion and a trading volume of 813,094 shares. For more details on the company's background, see its history and ownership or financial health.
Cytokinetics, Incorporated (CYTK) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.